Gotowa bibliografia na temat „Botulinum toxin – Therapeutic use”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Botulinum toxin – Therapeutic use”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Botulinum toxin – Therapeutic use"
Palazón-García, Ramiro, i Ana María Benavente-Valdepeñas. "Botulinum Toxin: From Poison to Possible Treatment for Spasticity in Spinal Cord Injury". International Journal of Molecular Sciences 22, nr 9 (5.05.2021): 4886. http://dx.doi.org/10.3390/ijms22094886.
Pełny tekst źródłaZbrojkiewicz, Małgorzata, Agata Lebiedowska i Barbara Błońska-Fajfrowska Barbara Błońska-Fajfrowska. "Botulinum toxin in medicine and cosmetology – two hundred years’ history and new perspectives". Postępy Higieny i Medycyny Doświadczalnej 72 (16.04.2018): 278–89. http://dx.doi.org/10.5604/01.3001.0011.7617.
Pełny tekst źródłaTugnoli, Valeria, Roberto Eleopra, Cesare Montecucco i Domenico De Grandis. "The therapeutic use of botulinum toxin". Expert Opinion on Investigational Drugs 6, nr 10 (październik 1997): 1383–94. http://dx.doi.org/10.1517/13543784.6.10.1383.
Pełny tekst źródłaMartina, Emanuela, Federico Diotallevi, Giulia Radi, Anna Campanati i Annamaria Offidani. "Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review". Toxins 13, nr 2 (5.02.2021): 120. http://dx.doi.org/10.3390/toxins13020120.
Pełny tekst źródłaIntiso, Domenico. "Therapeutic Use of Botulinum Toxin in Neurorehabilitation". Journal of Toxicology 2012 (2012): 1–12. http://dx.doi.org/10.1155/2012/802893.
Pełny tekst źródłaTaniosMarrelli, LorenaCury, Daniele MazzucaDominelli, IdibertoJosé ZotarelliFilho, LeandroMoreira Tempest i PatríciaGarani Fernandes. "THERAPEUTIC USE OF BOTULINUM TOXIN IN DENTISTRY". International Journal of Advanced Research 6, nr 10 (30.09.2018): 1219–22. http://dx.doi.org/10.21474/ijar01/7926.
Pełny tekst źródłaGhasemi, Majid, Rasul Norouzi, Mehri Salari i Bahador Asadi. "Iatrogenic Botulism After the Therapeutic Use of Botulinum Toxin-A". Clinical Neuropharmacology 35, nr 5 (2012): 254–57. http://dx.doi.org/10.1097/wnf.0b013e31826248b8.
Pełny tekst źródłaErbguth, Frank J. "Historical notes on botulism,Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin". Movement Disorders 19, S8 (2004): S2—S6. http://dx.doi.org/10.1002/mds.20003.
Pełny tekst źródłaEleopra, R., O. Rossetto i C. Montecucco. "Non-A/non-B botulinum toxin for therapeutic use". Toxicon 68 (czerwiec 2013): 73. http://dx.doi.org/10.1016/j.toxicon.2012.07.051.
Pełny tekst źródłaCorsalini, Massimo, Francesco Inchingolo, Gianna Dipalma, Angelika Elzbieta Wegierska, Ioannis Alexandros Charitos, Maria Assunta Potenza, Antonio Scarano i in. "Botulinum Neurotoxins (BoNTs) and Their Biological, Pharmacological, and Toxicological Issues: A Scoping Review". Applied Sciences 11, nr 19 (23.09.2021): 8849. http://dx.doi.org/10.3390/app11198849.
Pełny tekst źródłaRozprawy doktorskie na temat "Botulinum toxin – Therapeutic use"
Seifart, Anja. "The impact of functional electrical stimulation to the lower leg after a single botulinum toxin injection in children with a spastic equinus gait due to cerebral palsy". Thesis, Stellenbosch : Stellenbosch University, 2008. http://hdl.handle.net/10019.1/2860.
Pełny tekst źródłaCerebral palsy (CP) is a common neurological condition seen in children which results in childhood disability. Damage to the developing brain results in abnormal muscle tone and decreased force generation, which leads to loss of independent function. Previous studies investigating interventions targeting the typical equinus gait pattern seen in spastic CP have reported inconclusive and widespread outcomes. Objectives The objectives of the study were to determine (1) the effect of functional electrical stimulation (FES) after a single botulinum toxin injection into the triceps surae muscle as a functional orthosis on various gait parameters and economy of movement; (2) caregivers’ perceptions of the impact of the intervention on their child’s function and participation, and (3) optimal timing intervals for introducing FES after a botulinum toxin injection. Method Single-subject research with a multiple baseline approach was conducted on five ambulant subjects (average age 5.1 years, SD=1.4) in the Cape Metropole with a dynamic equinus gait due to hemiplegic CP. Two-dimensional gait analysis, isometric dynamometry, Energy Expenditure Index (EEI), and a caregiver questionnaire were used to gather data on walking speed, ankle angles at initial contact of gait, isometric plantarand dorsiflexior muscle strength, energy expenditure during gait, as well as caregiver perception on participation changes. Statistical analysis was conducted by means of ANOVA tests and graphic data illustrations. Results A statistically significant pre- to post intervention (FES after botulinum toxin) change was found for plantarflexor muscle strength. This effect was partially maintained over the withdrawal phase. Caregivers felt the intervention to have a positive influence on their children’s walking speeds, as well as on age-appropriate function and participation. Selfselected walking speed, dorsiflexor muscle strength, and ankle angles at initial contact did not change significantly. A 32-day interval between between botulinum toxin and the FES programme resulted in the most pronounced improvements in terms of walking speed, EEI scores, and plantarflexor muscle strength. Conclusion FES to the lower limb, 32 days after botulinum toxin into the triceps surae, applied for 30 minutes per day, five times a week over a total of four weeks, seemed to improve selected gait parameters as well as caregiver perception of impact on function and activities of daily living. However, further research is needed.
Redman, Toni Annette. "Upper limb Botulinum Toxin-A in children with hemiplegic cerebral palsy : physiological corticomotor pathways and effect on health related quality of life". University of Western Australia. Faculty of Medicine and Dentistry and Health Sciences, 2008. http://theses.library.uwa.edu.au/adt-WU2008.0123.
Pełny tekst źródłaCorry, Ian S. "Use of motion analysis laboratory in assessing the effects of botulinum toxin in cerebral palsy". Thesis, Queen's University Belfast, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.295345.
Pełny tekst źródłaLindsay, Cameron. "The early use of botulinum toxin in post stroke spasticity : developing a new approach to contracture management". Thesis, Keele University, 2018. http://eprints.keele.ac.uk/5173/.
Pełny tekst źródłaNg, Wai-yun Louisa, i 吳慧欣. "Production of variants of mitogillin with reduced IgE bindingactivity". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B31972093.
Pełny tekst źródłaTeixeira, Natacha Betânia Alves. "Toxina botulínica, considerações em medicina dentária". Master's thesis, [s.n.], 2014. http://hdl.handle.net/10284/4398.
Pełny tekst źródłaA toxina botulínica (TB) foi durante muito anos considerada um promotor de doença. No presente é considerada um agente terapêutico versátil para o tratamento de distúrbios musculares. O seu mecanismo de ação ocorre ao nível da fenda sináptica do músculo esquelético e leva a uma desnervação parcial e funcional dos neurónios motores, através da inibição da liberação do neurotransmissor de acetilcolina (Ach), juntamente com o bloqueio da libertação de outros neurotransmissores periféricos relacionados com a dor, que permite tenha uma ação antinociceptiva. Este trabalho consiste numa revisão bibliográfica narrativa que tem como objetivos abordar a estrutura e a síntese da TB, o seu mecanismo de acção e os diferentes aspectos farmacológicos e imunológicos associados à sua utilização terapêutica e abordar as diversas indicações de utilização ao nível da medicina dentária, nomeadamente, desordens temporomandibulares, distonias oromandibulares, bruxismo, sialorreia, cefaleia tensional, sorriso gengival e pós-operatório cirúrgico. As palavras-chaves utilizadas foram: ―Botulinum Toxin‖; ―Botulinum Toxin Type A‖; ―Temporomandibular Disorders‖; ―Bruxism‖; ―Gummy Smile‖; ―Myofascial Pain‖; ―Sialorrhoea‖; ―Tension Headache‖; ―Oromandibular Distonia‖; ―Masseter Hy-pertrophy‖; ―Temporoamdibular Joint Disc Displacement‖; ―Temporomandibular Joint Luxation‖; ―Pain‖; ―Clinical Use‖; ―Mechanism Of Action‖; ―Safety And Efficacy‖ combinadas de diversas formas. Nos últimos anos tem-se verificado o valor da TB no âmbito de diversas áreas da Medicina Dentária, no entanto, no seu enquadramento legal por parte da Ordem dos Médicos Dentistas, esta recomenda apenas a sua aplicação por parte de profissionais que tenham a devida formação e experiência. Botulinum toxin (BT) was for many years considered a promoter of disease. At present it is considered a versatile therapeutic agent for the treatment of muscular disorders. The mechanism of action of BT is at the level of the synaptic cleft of skeletal muscle and leads to a partial functional denervation of motor neurons by inhibiting the release of the neurotransmitter acetylcholine (Ach), together with blocking the release of other neurotransmitters related peripheral with pain, which allows it to have an antinociceptive action. This work consists in a narrative literature review that aims to deal with the structure and synthesis of BT, its mechanism of action and different pharmacological and immunological aspects related to its therapeutic use and discuss the its different uses in dentistry like in temporomandibular disorders, oromandibular dystonias, bruxism, drooling, tension headache, gummy smile surgery and postoperatively. The keywords used were: ―Toxin Botulinum‖; ―Botulinum Toxin Type A‖; ―Temporomandibular Disorders‖; ―Bruxism‖; ―Gummy Smile‖; ―Myofascial Pain‖; ―Sialorrhoea‖; ―Tension Headache‖; ―Oromandibular Distonia‖; ―Masseter Hy-pertrophy‖; ―Temporoamdibular Joint Disc Displacement‖; ―Temporomandibular Joint Luxation‖; ―Pain‖; ―Clinical Use‖; ―Mechanism Of Action‖; ―Safety And Efficacy‖ combined in various ways. In recent years BT has been used within various dentistry areas with success, however in a legal point of view, the Portuguese Dental Association leaves the recommendation that its use must be restrict to the professionals who have proper training and experience.
Preston, Nicholas John. "Does the use of home-based assistive rehabilitation technology enhance the functional benefits of botulinum toxin in children with cerebral palsy who have upper limb movement difficulties : a single-blind randomised controlled trial". Thesis, University of Leeds, 2014. http://etheses.whiterose.ac.uk/8075/.
Pełny tekst źródłaSalga, Marjorie. "Inflammation et paraostéoarthropathies neurogènes Blocking neuromuscular junctions with botulinum toxin A injection enhances neurological heterotopic ossification development after spinal cord injury in mice Traumatism brain injury: if neurological damage was not the key to the development of neurogenic heterotopic ossification? Corticosteroid injection is an alternative therapeutic strategy to treat pain in Neurogenic Heterotopic Ossification: a Case Series". Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLV072.
Pełny tekst źródłaHeterotopic ossifications (H0) are abnormal ectopic bone formations that develop in soft tissues. HO can be related to genetic factors or acquired pathologies. HO occurring after central nervous system lesion are called neurogenic HO (NHO). The objective of this project is to identify local and systemic inflammatory factors that may be associated with occurrence of NHO. We study first, the effect of bacterial membrane components on the development of NHO in a mouse model of spinal cord injury triggered by injection of a myotoxic compound into muscle. Local and systemic administration of membrane components from Escherichia coli or Staphylococcus aureus significantly increased the volume of NHO. Changes in the level of inflammation, which was dose responsive, correlated with changes in NHO volume suggesting that inflammation influences NHO formation. As bacterial membrane components were also linked to increased volumes of NHO, it is possible that inflammation triggered by infectious pathogens could also be involved in NHO development. Furthermore, we identified that after reaching a certain threshold of inflammation, triggered by administration of bacterial membrane components, spinal cord injury was not required for NHO formation. Further experiments with this model involved determining the effect of blocking neuromuscular signaling on NHO formation. Botulinum toxin injection increased the size of NHO. Therefore, neuromuscular signaling also modulates NHO development in damaged muscles of spinal cord-injured mice. By extension, local neuroinflammation was implicated in regulating neuromuscular signals received by affected muscles. Based on these preclinical results, we carried out a case-control study to look for factors inducing inflammation that could be linked with NHO occurrence, and which occur at early stages after neurological trauma. This study identifies for the first time that patients with Pseudomonas Aeruginosa-positive infections were more likely to develop NHO. NHO patients more frequently experience surgery and polytrauma, compared to patients without NHO. Furthermore, extended stays in intensive care, long periods of mechanical ventilation, enduring coma, or patients with a tracheotomy were more frequent in patient with NHO. In contrast, no neurological factors were associated with a higher risk of developing NHO. Patients with comparable neurological trauma severity were more susceptible to develop NHO when they were experiencing a high level of inflammation (infection, polytrauma, surgeries, intensive care). Like for other inflammatory joint pathologies, we performed a further study which involved the infiltration of NHO with corticosteroid locally, in order to treat pain induced by NHO formation. One month after treatment, 80% of patients reported an improvement of pain. Therefore, we demonstrate that corticosteroid infiltration at the site of NHO is an effective treatment for pain associated with NHO. Detecting patients that are at risk to develop NHO as early as possible after an accident is imperative, to adapt rehabilitative strategies or treatment needs specific for patients that develop NHO. However, NHO diagnosis occurs during late phase of disease, when complications are occurring. To address this shortfall in the detection of NHO formation, we are undertaking the first prospective study of NHO, where clinical and biological information will be recorded to make a database. The specific data to be collected has been defined by our previous research in the mouse model and earlier clinical studies, and will identify specific biological and clinical factors that can be monitored to identify patients at risk to develop NHO. The outcomes of this project have specific implications in the understanding the drivers of NHO formation and its detection. Global outcomes of this project include improving patient management and possibly the prevention of NHO formation in patients
Joussain, Charles. "Construction and validation of HSV-1 vectors with selective and long-term expression in bladder afferent neurons for gene therapy of neurogenic detrusor overactivity. : A translational approach Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons Development and assessment of herpes simplex virus type 1 (HSV-1) amplicon vectors with expression from sensory neuron-selective promoters. Construction and properties of replication-incompetent HSV-1 recombinant vectors expressing transgenic botulinum toxins in primary cultures of human sensory neurons and displaying long-term expression in vivo. Therapeutic escalation for the neurogenic bladder in SCI patients : A bicentric study real life experience Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity". Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLV057.
Pełny tekst źródłaFifty to 80% of patients with traumatic spinal cord injury (SCI) undergo urinary incontinence episodes, mostly related to neurogenic detrusor overactivity (NDO). NDO is characterized by uninhibited detrusor contractions during the bladder-filling phase which could lead to a significant increase in bladder pressures, especially when associated to sphincter-destrusor-dyssynergia, leading to uro-nephrological complications. The main goal of NDO management following SCI is to achieve regular and complete bladder emptying, avoiding high intra-detrusor pressure and maintaining continence, in order to improve patients’ quality of life and to prevent renal failure. The current management is well characterized and relies on pharmacotherapy acting primarily at the level of efferent motor micturition reflex branch, thus allowing bladder filling at low pressure. First line treatment relies on oral antimuscarinics, often associated to clean intermittent bladder self-catheterization. When patients are refractory to antimuscarinics, injection of botulinum toxin A into the detrusor is proposed. However, despite their efficacy, these treatments fail to persist in the long term, leading to a third-line surgical treatment, which consists in cystoplasty augmentation or sacral neuromodulation. The Brindley technique, which consist in a sacral deafferentation of bladder posterior roots associated to an electrical stimulation, on demand, of anterior roots is a promising alternative, but remains seldom performed because of the complex surgical procedure required. NDO results from the emergence, secondary to neuronal plasticity following SCI, of an abnormal micturition reflex mediated by bladder afferent C-fibers, conveying aberrant sensory information to the spinal cord. The aim of the team where I developed my work is to silence these bladder afferent C-fibers in order to abolish the impaired spinal micturition reflex after SCI. In a second time, micturition would be fired, on demand, by electric stimulation of the bladder efferent neurons. My work consisted in developing the tools and methods required for such molecular deafferentation. Accordingly, I constructed replication-incompetent HSV-1 vectors conceived to deliver a therapeutic transcription cassette, consisting in the light chains of botulinum toxin (BoNT-LC) driven by the human version of the promoter of the gene encoding calcitonin gene-related protein (hCGRP), to achieve sensory neuron-selective transgenic expression. The transcription cassette was inserted into the LAT locus of the HSV-1 genome, the only region of the virus genome that remains transcriptionally active during latent infection. These vectors have been assessed (i) in vitro, on cell lines of neural origin and on primary cultures of rat embryonic and adult sensory neurons, and on primary cultures of adult human sensory and sympathetic neurons, (ii) ex vivo, on organotypic cultures of sensory, sympathetic and parasympathetic ganglia from adult rats, and (iii) in vivo, in sensory ganglia following infection at the hind footpad of adult rats.Our results indicate that (i) the vectors express functional BoNT-LC, thereby cleaving proteins of the SNARE complex in rat and human sensory neurons and inhibiting release of the neuromediator CGRP in rat sensory neurons, (ii) the transcription cassette delivered by the vectors display highly selectively expression towards human sensory neurons, as compared to human sympathetic neurons, and (iii) the vectors induced long-term transgenic expression in sensory (DRG) ganglia (at least for three months) following footpad injection. Therefore, the vectors seem to accomplish the three main specifications required for a future gene therapy strategy, allowing to restore urinary continence and micturition without catheterization and without any major surgery. This approach will represent a major breakthrough in the management of NDO in SCI patients with complete and incomplete lesion
Silva, Cláudia Sofia Dionísio. "Use of Botulinum Toxin for Refractory Trigeminal Neuralgia". Master's thesis, 2018. https://repositorio-aberto.up.pt/handle/10216/112186.
Pełny tekst źródłaKsiążki na temat "Botulinum toxin – Therapeutic use"
NIH Consensus Development Conference on Clinical Use of Botulinum Toxin (1990 Bethesda, Md.). Botulinum toxin. Bethesda, Md: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, Office of Medical Applications of Research, 1990.
Znajdź pełny tekst źródłaJoseph, Jankovic, red. Botulinum toxin: Therapeutic clinical practice & science. Philadelphia, PA: Saunders/Elsevier, 2008.
Znajdź pełny tekst źródłaBotulinum-toxin therapy. Stuttgart: Thieme, 2000.
Znajdź pełny tekst źródłaBotulinum neurotoxins. Heidelberg: Springer, 2013.
Znajdź pełny tekst źródłaChancellor, Michael B. Botulinum toxin in urology. Heidelberg: Springer, 2011.
Znajdź pełny tekst źródłaJoseph, Jankovic, i Hallett Mark, red. Therapy with botulinum toxin. New York: M. Dekker, 1994.
Znajdź pełny tekst źródłaCooper, Grant, red. Therapeutic Uses of Botulinum Toxin. Totowa, NJ: Humana Press, 2007. http://dx.doi.org/10.1007/978-1-59745-247-2.
Pełny tekst źródłaFRCP, Moore Peter, red. Handbook of botulinum toxin treatment. Oxford [England]: Blackwell Science, 1995.
Znajdź pełny tekst źródłaGluckstein, Fritz P. Clinical use of botulinum toxin: January 1987 through September 1990, 318 citations. Bethesda, Md: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Library of Medicine, Reference Section, 1990.
Znajdź pełny tekst źródłaGluckstein, Fritz P. Clinical use of botulinum toxin: January 1987 through September 1990 : 318 citations. Bethesda, Md: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Library of Medicine, Reference Section ; Washington, D.C. : For sale by the Supt. of Docs., U.S. G.P.O., 1990.
Znajdź pełny tekst źródłaCzęści książek na temat "Botulinum toxin – Therapeutic use"
Wan, Michael J., Sara AlShaker i David G. Hunter. "Use of Botulinum Toxin in Ophthalmology". W Botulinum Toxin Therapy, 147–60. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/164_2019_325.
Pełny tekst źródłaChancellor, Michael B., i Christopher P. Smith. "Use of Botulinum Toxin in the Genitourinary System". W Botulinum Toxin Therapy, 171–84. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/164_2019_308.
Pełny tekst źródłaWan, Michael J., Sara AlShaker i David G. Hunter. "Correction to: Use of Botulinum Toxin in Ophthalmology". W Botulinum Toxin Therapy, 283. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/164_2020_413.
Pełny tekst źródłaWollmer, M. Axel, Michelle Magid, Tillmann H. C. Kruger i Eric Finzi. "The Use of Botulinum Toxin for Treatment of Depression". W Botulinum Toxin Therapy, 265–78. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/164_2019_272.
Pełny tekst źródłaLi, Sheng, i Gerard E. Francisco. "The Use of Botulinum Toxin for Treatment of Spasticity". W Botulinum Toxin Therapy, 127–46. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/164_2019_315.
Pełny tekst źródłaBerardelli, Alfredo, i Antonella Conte. "The Use of Botulinum Toxin for Treatment of the Dystonias". W Botulinum Toxin Therapy, 107–26. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/164_2019_339.
Pełny tekst źródłaYuan, Hsiangkuo, i Stephen D. Silberstein. "The Use of Botulinum Toxin in the Management of Headache Disorders". W Botulinum Toxin Therapy, 227–49. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/164_2020_365.
Pełny tekst źródłaWollmer, M. Axel, Michelle Magid, Tillmann H. C. Kruger i Eric Finzi. "Correction to: The Use of Botulinum Toxin for Treatment of Depression". W Botulinum Toxin Therapy, 279. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/164_2020_411.
Pełny tekst źródłaLi, Sheng, i Gerard E. Francisco. "Correction to: The Use of Botulinum Toxin for Treatment of Spasticity". W Botulinum Toxin Therapy, 281. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/164_2020_412.
Pełny tekst źródłaBerardelli, Alfredo, i Antonella Conte. "Correction to: The Use of Botulinum Toxin for Treatment of the Dystonias". W Botulinum Toxin Therapy, 285. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/164_2020_414.
Pełny tekst źródłaStreszczenia konferencji na temat "Botulinum toxin – Therapeutic use"
Figueiredo, Camila Angelo Vidal de, Kaline dos Santos Kishishita Castro i Sílvia Raimunda Costa Leite. "Therapeutic management of movement disorders present in Huntington’s Disease: a literature review". W XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.430.
Pełny tekst źródłaSternlieb, S. J., S. Ferrell, S. P. Kantrow i G. Lea. "Pyridostigmine for Therapeutic Botulinum Toxin Reversal in Adult". W American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2404.
Pełny tekst źródłaGarrido, João Guilherme Santos, João Gustavo dos Anjos Morais Oliveira, Luana Brandão de Sales Reis, Beatriz do Nascimento Garcia Moreno i Ricardo Moreno do Carmo Junior. "Benefits of Botulinum Toxin type A in post-stroke neurorehabilitation". W XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.360.
Pełny tekst źródłaTaylor, Graham, Donald Leo i Andy Sarles. "Detection of Botulinum Neurotoxin/A Insertion Using an Encapsulated Interface Bilayer". W ASME 2012 Conference on Smart Materials, Adaptive Structures and Intelligent Systems. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/smasis2012-8101.
Pełny tekst źródłaSantos, Gabriel Cerqueira, Caio de Almeida Lellis, Bruno Coelho Duarte Oliveira, Letícia Romeira Belchior, Caíque Seabra Garcia de Menezes Figueiredo i Ledismar José da Silva. "Botulinum toxin type A in the treatment of Myofascial Pain Syndrome: A Systematic Review". W XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.263.
Pełny tekst źródłaLemos, Gabrielle Torres Oliveira, Gabriel das Chagas Benevenuto, Gabriela Guy Duarte, Bruno Alves Pinto i Ivan Magalhães Viana. "The use of Botulinum toxin type A for the treatment of refractory chronic migraine". W XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.566.
Pełny tekst źródłaPopescu, Mara, Jochen Kammermeier, Rakesh Vora i Mohamed Mutalib. "G14 The use of pyloric EndoFLIP to assess response to botulinum toxin injection in children". W Abstracts of the BSPGHAN Annual Meeting, 25–27 April 2022. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/flgastro-2022-bspghan.34.
Pełny tekst źródłaPinheiro, Renato Serquiz Elias, Emanuelly da Costa Nobre Soares, Maria Eduarda Bezerra Figueiredo i Stella Mandu Cicco. "Pisa syndrome in Parkinson’s disease: case description". W XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.644.
Pełny tekst źródłaRaporty organizacyjne na temat "Botulinum toxin – Therapeutic use"
Cairo, Jessica, Iulia Gherman i Paul Cook. The effects of consumer freezing of food on its use-by date. Food Standards Agency, lipiec 2021. http://dx.doi.org/10.46756/sci.fsa.ret874.
Pełny tekst źródłaSafe and effective use of botulinum toxin for refractory LUTS. BJUI Knowledge, grudzień 2016. http://dx.doi.org/10.18591/bjuik.0053.
Pełny tekst źródła